Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rechallenge With H10N7 Influenza Virus in Healthy Volunteers
NCT07215871Phase 1Enrolling by invitation
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Apr 2026
- Primary completion
- Sep 2027
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of A/Mallard/Ohio-99/MM4/1989 H10N7 in influenza, sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Rate of Mild-to-Moderate Influenza Disease (MMID) at 9 days. Started Apr 2026; status: enrolling by invitation.
02
Drugs
A/Mallard/Ohio-99/MM4/1989 H10N7
03
Conditions
influenza
Beyond the preview
Go deeper on NCT07215871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07215871.